Novocure Reports Third Quarter 2019 Financial Results and Provides Company Update
Quarterly net revenues of $92.1 million, representing 42% growth versus the third quarter 2018 First quarter ever of positive net income with $0.02 in earnings per share Continued clinical progress with four ongoing phase 3 pivotal trials creating the potential for substantial market expansion over the next five years ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) …